OncoMatch/Clinical Trials/NCT06780670
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Is NCT06780670 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Investigators choice of SoC and AAA817 for prostate cancer.
Treatment: Investigators choice of SoC · AAA817 · AAA817 · AAA817 — This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 psma-positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen receptor pathway inhibitor
Prior treatments with an androgen receptor pathway inhibitor (ARPI)
Must have received: taxane
Prior treatments with ... taxane-based chemotherapy
Must have received: PSMA-targeted radioligand therapy ([177Lu]Lu-PSMA)
progressed on or after [177Lu]Lu-PSMA targeted therapy
Cannot have received: investigational agent
Any investigational agents within 28 days prior to the day of randomization
Cannot have received: 225Ac-based investigational compound
Any 225Ac-based investigational compound used prior to the day of randomization
Lab requirements
Kidney function
egfr as requested by the sponsor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- VA Greater LA Healthcare System · Los Angeles, California
- University Cancer and Blood Center LLC · Athens, Georgia
- Indiana University · Indianapolis, Indiana
- University of Kansas Hospital · Kansas City, Kansas
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify